Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer
NCT03211416Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2017
- Primary completion
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Overall Response Rate at 6 months. Started Dec 2017; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03211416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03211416.